Patent SG-11201809497R-A (SG)
Title: Processes for preparing phosphorodiamidate morpholino oligomers
Inventor: CAI BAO
IPC: C07D265/30
Filed: 2017-06-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) °mint H IDIIIDIDIIl Elan EH 011 (10) International Publication Number WO 2017/205880 Al WIPO I PCT (51) International Patent Classification: A61K 31/496 (2006.01) C07D 265/30 (2006.01) A61K 31/5377 (2006.01) (21) International Application Number: PCT/US2017/040318 (22) International Filing Date: 30 June 2017 (30.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,049 24 May 2016 (24.05.2016) US 62/340,953 24 May 2016 (24.05.2016) US 62/357,134 30 June 2016 (30.06.2016) US 62/357,166 30 June 2016 (30.06.2016) US 62/508,256 18 May 2017 (18.05.2017) US (71) Applicant: SAREPTA THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02139 (US). (72) Inventors: CAI, Bao; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). MARTINI, Mitchell; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). THOMAS, Katie; c/o Sarep- ta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). SHIMABUKU, Ross; c/o Sarepta Therapeu- tics, Inc., 215 First Street, Cambridge, MA 02142 (US). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii)) (74) Agent: TRINQUE, Brian, C. et al.; Lathrop & Gage, LLP, 28 State Street, Boston, MA 02109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 1-1 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, O MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, pp TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). O N (54) Title: PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS 0 (57) : Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described \" herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.